Medidata has expanded a multi-year collaboration with Catalyst Clinical Research for oncology clinical trials.

Under the expanded alliance, Medidata will offer support for Catalyst Oncology, an oncology brand of Catalyst Clinical Research.

The new partnership includes solutions comprising Medidata Grants Manager and Medidata AI Intelligent Trials.

Renewal of the deal builds on the success of Catalyst in leveraging the Medidata Platform earlier.

The continued support for Medidata Rave CTMS, Medidata Rave EDC and Medidata Rave eTMF will allow Catalyst in streamlining its activities and management and conducting complex trials.

Uniting this expertise with Grants Manager and Intelligent Trials, Catalyst will also be able to simplify workflows, carry out document management automation and enhance visibility to vital trial criteria.

Catalyst Clinical Research president and COO Nik Morton said: “Medidata remains our preferred partner because of their scalability and skill in managing complex trials. 

“Their advanced technology will further support our growth and expansion.”

Catalyst provided support for more than 150 trials in the oncology field and is presently overseeing more than 80 Phases I-III 'next-generation' cancer trials. 

Medidata Partners senior vice-president Joan Shaiman said: “Medidata is thrilled to serve as Catalyst’s partner since their first trial in 2019 and be part of their continued success. 

“Their decision to recommit to the core elements of our Platform and adopt broader solutions demonstrates that we have the expertise and capabilities needed to support faster decision-making and accelerate trials to advance cancer research.”

In September this year, the company launched the Medidata Diversity Program to enhance diversity, equity, and inclusion in trials.